Skip to Main Content

Paper Details

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
Nat Commun
90
2018
AR, AR+, AR+ CRPC, AR+ and AR-knockout LNCaP cell clones, AR-, AR-/lo CRPC, AR-/lo PCa cells, BCL-2, CRPC, PCa, PCa cells, androgen, androgen receptor, castration-resistant PCa, enzalutamide, nuc/cyto-AR, patients, prostate cancer, prostate cancer cell, prostate tumor
Author NameAffiliation
Yue LuUniversity of Texas M.D. Anderson Cancer Center
Jiaoti HuangDuke University of School of Medicine
Mark A RubinCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College
Mark A RubinSandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Mark A RubinCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College
Mark A RubinSandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Himisha BeltranCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College
Himisha BeltranSandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Himisha BeltranCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College
Himisha BeltranSandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Jianjun ShenUniversity of Texas M.D. Anderson Cancer Center
Jianmin WangRoswell Park Comprehensive Cancer Center
  • 1 - 12

Datasets

Release 1.2